4-氟-3-(吗啉-4-羰基)苯硼酸 | 874219-29-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-3-(吗啉-4-羰基)苯硼酸
• 中文别名: 4-氟-3-(吗啉-4-羰基)苯基硼酸
• 英文名称: (4-fluoro-3-(morpholine-4-carbonyl)phenyl)boronic acid
• 英文别名: 4-Fluoro-3-(morpholine-4-carbonyl)phenylboronic acid；[4-fluoro-3-(morpholine-4-carbonyl)phenyl]boronic acid
• CAS: 874219-29-1
• 化学式: C₁₁H₁₃BFNO₄
• 分子量: 253.038
• InChiKey: DLQOQRNXQBBPSO-UHFFFAOYSA-N

物化性质

• 熔点：
  138-140
• 沸点：
  496.7±55.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.02
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi

反应信息

• 作为反应物：
  描述：

  4-bromo-6-(but-3-en-1-yl)-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one 、 4-氟-3-(吗啉-4-羰基)苯硼酸 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 水 、 乙腈 为溶剂， 反应 0.17h， 生成 6-but-3-enyl-4-[4-fluoro-3-(morpholine-4-carbonyl)phenyl]-1H-pyrrolo[2,3-c]pyridin-7-one
  参考文献：
  名称：

  GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like

  摘要：

  The biological functions of the dual bromodomains of human transcription-initiation-factor TFIID subunit 1 (TAF1(1,2)) remain unknown, although TAF1 has been identified as a potential target for oncology research. Here, we describe the discovery of a potent and selective in vitro tool compound for TAF1(2), starting from a previously reported lead. A cocrystal structure of lead compound 2 bound to TAF1(2) enabled structure-based design and structure-activity-relationship studies that ultimately led to our in vitro tool compound, 27 (GNE-371). Compound 27 binds TAF1(2) with an IC(50 )of 10 nM while maintaining excellent selectivity over other bromodomain-family members. Compound 27 is also active in a cellular-TAF1(2) target-engagement assay (IC50 = 38 nM) and exhibits antiproliferative synergy with the BET inhibitor JQ1, suggesting engagement of endogenous TAF1 by 27 and further supporting the use of 27 in mechanistic and target-validation studies.

  DOI：

  10.1021/acs.jmedchem.8b01225

文献信息

• Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
  申请人：Amgen Inc.

  公开号：US07820665B2

  公开（公告）日：2010-10-26

  The present invention relates to imidazopyridazine compounds of Formula I, such as representative structure A, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

  本发明涉及公式I的咪唑吡啶二氮杂化合物，例如代表性结构A，或其药学上可接受的盐，其抑制磷脂酰肌醇3-激酶；使用该化合物治疗疾病或病况的方法，例如癌症；以及包含该化合物的药物组合物。
• Aminopyridine Derived Compounds as LRRK2 Inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20160184317A1

  公开（公告）日：2016-06-30

  The present invention is directed to aminopyridine derived compounds of formula (A) The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.

  本发明涉及公式（A）的氨基吡啶衍生物化合物。这些化合物被认为对于与LRRK2相关的疾病的治疗是有用的，例如Lewy体痴呆症、帕金森病或癌症。
• Aminopyridine derived compounds as LRRK2 inhibitors
  申请人：H. Lundbeck A/S

  公开号：US20150336942A1

  公开（公告）日：2015-11-26

  The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.

  本发明涉及公式（A）的氨基吡啶衍生物化合物。这些化合物被认为对于与LRRK2相关的疾病，如Lewy体痴呆、帕金森病或癌症的治疗是有用的。
• Inhibitors of PI3 kinase
  申请人：Booker Shon

  公开号：US20090163489A1

  公开（公告）日：2009-06-25

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

  本发明涉及公式I的化合物或其药学上可接受的盐，其抑制磷脂酰肌醇3-激酶；使用这些化合物治疗疾病或病症的方法，例如癌症；以及含有这些化合物的药物组合物。